Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph...

Prof Robin Foa - University of Rome, Rome, Italy

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany

$Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )$

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Multiple myeloma science from EHA 2019

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

$Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )$

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

More from ecancer